IP Library › Granted Patent US 11,926,633
Granted Patent B2
US 11,926,633 · App. 17/272,369 · Granted Mar 12, 2024

Synthesis methods for upadacitinib and intermediate thereof

Inventors: Peng Wang (Suzhou, CN); Pixu Li (Suzhou, CN); Qiang Wei (Suzhou, CN); Wen Cheng (Suzhou, CN); Hao Wu (Suzhou, CN)
Assignee: SUZHOU PENGXU PHARMATECH CO., LTD
C07D487/14C07D207/08C07D207/16C07D241/20C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,926,633
App. No.
17/272,369
Granted
Mar 12, 2024
Kind
B2
Abstract

The present disclosure relates to a JAK inhibitor upadacitinib intermediate and a preparation method therefor, and to a preparation method for a JAK inhibitor upadacitinib. The upadacitinib intermediate of the present application is as shown in Formula (II) or Formula (III), wherein, R is a protective group of nitrogen atoms, and R 1 is an open-chain or cyclic amine group. Compared with the prior art, the method for the synthesis of upadacitinib of the present application, significantly reduces cost, is environmentally-friendly. And the quality of the final product is well controlled.

Claims (4)

1. A compound, having a structure shown Formula III:

wherein, R is a protective group of nitrogen atoms.

2. The compound according to claim 1 , wherein,

in Formula III, R is selected from the group consisting of benzyl, benzyloxycarbonyl, and allyloxycarbonyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2021
From: WANG, PENG; LI, PIXU; WEI, QIANG; CHENG, WEN; WU, HAO
To: SUZHOU PENGXU PHARMATECH CO., LTD
Reel/Frame 055440/0455 →
Priority Claims (2)
CN 201811008444.4 · Aug 31, 2018 · national
CN 201811083531.6 · Sep 17, 2018 · national
Continuity (1)
Related Publication 20210323971A1 · Oct 21, 2021